DPL responds to HHS RFI for IPI drug pricing model (Nov. 30, 2018)
The Drug Pricing Lab responds to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs. We support the Administration’s efforts to evaluate possible improvements to the purchasing and reimbursement process for Part B drugs. In addition to indexing reimbursement prices to some international prices, we highlight some elements of the design that we think will improve the evaluation at the time of completion, suggest reintroducing the Competitive Acquisition Program but in a controlled manner, and replacing percent-based markups with a flat fee payment.
Download our full response here.